This study aimed to explore biomarkers in Huntington’s disease (HD) using various multi-omics platforms to profile a selection of both clinical and preclinical samples. By employing both targeted and untargeted approaches in proteomics, lipidomics, and metabolomics, we sought to identify molecular signatures that could enhance understanding of disease progression and inform the development of targeted treatments.
Poster
View the poster here:
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.
